AGR2 knockdown by siRNA, shRNA, and miRNA in ER+ breast cancer lines reduces growth, survival, and migration, as well as fulvestrant and tamoxifen resistance [12, 17–19]. This evidence concerns the gene AGR2 and breast carcinoma.